
Pivanex
CAS No. 122110-53-6
Pivanex ( AN-9 | Pivalyloxymethyl butyrate )
产品货号. M26790 CAS No. 122110-53-6
Pivanex 是一种口服活性 HDAC 抑制剂和抗转移剂和抗血管生成剂。 Pivanex 下调 Bcr-Abl 蛋白并增强细胞凋亡。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥316 | 有现货 |
![]() ![]() |
10MG | ¥478 | 有现货 |
![]() ![]() |
25MG | ¥988 | 有现货 |
![]() ![]() |
50MG | ¥1531 | 有现货 |
![]() ![]() |
100MG | ¥2333 | 有现货 |
![]() ![]() |
200MG | ¥3467 | 有现货 |
![]() ![]() |
500MG | ¥5557 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Pivanex
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Pivanex 是一种口服活性 HDAC 抑制剂和抗转移剂和抗血管生成剂。 Pivanex 下调 Bcr-Abl 蛋白并增强细胞凋亡。
-
产品描述Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.(In Vitro):In K562 cells, Pivanex (100-500 μM) exhibits significant anti-proliferation activity and enhances apoptosis and caspase activity. Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase, and a slight reduction in G0-G1 of the cell cycle.(In Vivo):Pivanex(200 mg/kg, b.i.d, daily) treatment marked delays in the end stage of disease as defined by the onset of body mass loss by 94.9%. Pivanex(200 mg/kg, b.i.d, daily) obviously improves the survival of SMN7 SMA mice by 84.6%.
-
体外实验Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.Pivanex (200 μM)induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Cell Viability Assay Cell Line:K562 cells.Concentration:100-500 μM.Incubation Time:24 hours.Result:Reduced the number of K562 viable cells significantly.100 μM Pivanex with 0.125 or 0.25 μM STI571 reduced the number of viable cells synergistically.Apoptosis Analysis Cell Line:K562 cells.Concentration:100-500 μM.Incubation Time:6-72 hours.Result:Increased the number of K562 apoptotic cells significantly.Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500 μM.
-
体内实验Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss. Animal Model:SMN7 SMA mice (SMN2+/+; SMN7+/+; mSmn?/?).Dosage:200 mg/kg.Administration:Oral administration, b.i.d, at 09.00 and 17.00 daily.Result:Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%.
-
同义词AN-9 | Pivalyloxymethyl butyrate
-
通路Apoptosis
-
靶点Apoptosis
-
受体GSK-3α| GSK-3β
-
研究领域——
-
适应症——
化学信息
-
CAS Number122110-53-6
-
分子量202.25
-
分子式C10H18O4
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : ≥ 100 mg/mL (494.44 mM)
-
SMILESCCCC(=O)OCOC(=O)C(C)(C)C
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Prabhakaran J, et al. Radiosynthesis and in Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain. ACS Chem Neurosci. 2017 Aug 16;8(8):1697-1703.
产品手册




关联产品
-
BiP inducer X
BiP 诱导剂 X 是免疫球蛋白重链结合蛋白 (BiP)/GRP78 的选择性诱导剂和 ER 伴侣诱导剂。 BiP 诱导剂 X 可防止神经元和视网膜细胞系的细胞死亡。
-
Bcl-B inhibitor 1
Bcl-B inhibitor 1 是 Bcl-B 的抑制剂。
-
AGN 192870
AGN 192870 是一种 RAR 中性拮抗剂,对 RARα、RARβ 和 RARγ 的Kd 分别为 147、33 和 42 nM。AGN 192870 对于 RARα 和 RARγ 的 IC50 分别为 87 和 32 nM。AGN 192870 显示 RARβ 部分激动作用。